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Patients with sporadic Hirschsprung disease (HSCR) show increased allele sharing at markers in the 5′ region of
the RET locus, indicating the presence of a common ancestral RET mutation. In a previous study, we found a
haplotype of six SNPs that was transmitted to 55.6% of our patients, whereas it was present in only 16.2% of
the controls we used. Among the patients with that haplotype, 90.8% had it on both chromosomes, which led to
a much higher risk of developing HSCR than when the haplotype occurred heterozygously. To more precisely define
the HSCR-associated region and to identify candidate disease-associated variant(s), we sequenced the shared com-
mon haplotype region from 10 kb upstream of the RET gene through intron 1 and exon 2 (in total, 33 kb) in a
patient homozygous for the common risk haplotype and in a control individual homozygous for the most common
nonrisk haplotype. A comparison of these sequences revealed 86 sequence differences. Of these 86 variations, 8
proved to be in regions highly conserved among different vertebrates and within putative transcription factor binding
sites. We therefore considered these as candidate disease-associated variants. Subsequent genotyping of these eight
variants revealed a strong disease association for six of the eight markers. These six markers also showed the largest
distortions in allele transmission. Interspecies comparison showed that only one of the six variations was located
in a region also conserved in a nonmammalian species, making it the most likely candidate HSCR-associated variant.
Hirschsprung disease (HSCR [MIM 142623]) is caused
by the absence of intrinsic ganglion cells in the myenteric
and submucosal plexuses of the gastrointestinal tract, re-
sulting in severe intestinal obstructions. HSCR is a het-
erogenic disorder: a number of genes have been shown
to play a role in the disease etiology (Holschneider 1982;
Badner et al. 1990; Amiel and Lyonnet 2001). The RET
gene (MIM 164761) is a main factor in HSCR devel-
opment. RET encodes a transmembrane tyrosine kinase
receptor, a protein responsible for triggering a number of
downstream signaling pathways involved in crucial pro-
cesses, such as neural crest cell differentiation, migration,
and proliferation (Manie et al. 2001). Mutations in RET
have been found in up to 50% of familial cases of HSCR.
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For the more common sporadic form of HSCR, RET
coding mutations have been found in not more than 20%
of patients (Hofstra et al. 2000; Amiel and Lyonnet 2001).
Several studies have shown, however, that the RET locus
is linked to the disease in almost all familial cases, re-
gardless of their mutation status (Bolk et al. 2000; Gabriel
et al. 2002), and is also associated with HSCR in a large
proportion of the patients with sporadic HSCR who do
not have RET coding mutations. Furthermore, recently
published articles revealed that similar haplotypes are
found in the 5′ region of the RET locus in patients from
several European populations with HSCR (Borrego et al.
2003; Fitze et al. 2003; Sancandi et al. 2003; Burzynski
et al. 2004), indicating the segregation of the same an-
cestral mutation(s) in the whole European population of
patients with HSCR. The identified region of association
comprises intron 1 of the RET gene and, depending on
the markers genotyped by the different groups, different
lengths of upstream genomic sequence (Borrego et al.
2003; Fitze et al. 2003; Sancandi et al. 2003; Burzynski
et al. 2004). In a previous study, we found that a hap-
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Table 1
Sequence Variations in the Common Risk
Haplotype, as Compared with the Most
Common Nonrisk Haplotype
Position and Type
of Variant
NCBI dbSNP
Accession No.
9557GrC …
9341CrT rs3026719
9256CrG rs2505989
7359ArC rs2505990
6347GrA rs2505991
6093TrC …
5669GrC rs2505992
4636GrC rs732610
4361CrGa,b rs741763
4201GrA rs2082107
4146CrG …
3820CrT rs2505994
3054GrA rs2505995
2897TrC rs2505996
2352TrC rs2505997
1782GrA rs2505998
1260TrC rs2505999
719CrT rs2435366
200GrA (SNP-5)a,c rs10900296
196ArC (SNP-1)a,c rs10900297
IVS1620CrA rs3123712
IVS1779TrC rs2506010
IVS11813CrT rs2435365
IVS12157CrT rs2506011
IVS12820TrC rs1864411
IVS12846GrT rs1864410
IVS13104CrT rs1864408
IVS13442ArG rs2506013
IVS13460CrT rs2435364
IVS13470GrA …
IVS13788CrG rs2506014
IVS13991del12 …
IVS14247CrG rs2506015
IVS15094TrA rs2506016
IVS15274insCT …
IVS16000CrAa,b rs2435362
IVS16136GrT rs2506019
IVS16174GrA rs2435361
IVS16294TrC rs2506020
IVS16383GrC …
IVS16384GrC …
IVS16411GrA …
IVS16751TrC rs1897001
IVS16757ArG rs1897000
IVS16813CrT rs1896999
IVS17236GrA rs2435359
IVS17436ArG rs2435358
IVS17445ArC rs2506008
IVS17994CrG rs2506007
IVS19494CrA rs2506004
IVS110371GrA rs2435356
IVS110813ArG …
IVS111369TrC rs2506021
IVS111476CrT rs2435342
IVS111490TrC rs2506022
IVS111084insG …
IVS110285GrT rs2435343
(continued)
Table 1 (continued)
Position and Type
of Variant
NCBI dbSNP
Accession No.
IVS110032CrT rs2435344
IVS110017CrT rs2435345
IVS19651TrG …
IVS18047CrT rs2506023
IVS17593GrA rs752975
IVS17525CrT rs752977
IVS17477TrA rs752978
IVS17298GrA …
IVS16988GrA rs2506024
IVS16567CrG …
IVS16566GrC …
IVS16393ArG …
IVS16257GrC rs3128726
IVS15791CrT rs2505541
IVS15666CrT rs2505540
IVS15127CrG …
IVS15107TrC …
IVS15038CrT rs2505539
IVS15005ArG rs2435346
IVS14925GrA …
IVS14503GrA rs2505538
IVS14073CrA …
IVS13748CrT rs2505537
IVS13702TrA rs2505536
IVS12863GrA rs2505535
IVS1891ArT …
IVS1888GrCa …
IVS1881CrT …
c135GrA (exon 2)d rs1800858
NOTE.—Positions of variations localized up-
stream the gene refer to RET ATG.
a SNPs from our previously characterized six-
locus ancestral haplotype.
b Previously reported in Burzynski et al. 2004.
c Previously reported in Sancandi et al. 2003.
d Previously reported in Ceccherini et al. 1994.
lotype consisting of six SNPs, spanning 27 kb (from 4 kb
upstream of the gene through the whole intron 1), was
transmitted from the parents in 55.6% of our patients
with sporadic HSCR and was not transmitted in only
16.2% (Burzynski et al. 2004). Moreover, for individuals
homozygous for the risk haplotype, the odds ratio to de-
velop HSCR was 21.9, whereas, for the heterozygotes, it
was 2.2, suggesting dose dependence of the unknown var-
iants (Burzynski et al. 2004). Three groups tried to cor-
relate specific haplotypes of two SNPs (which were also
part of our risk haplotype) located in the basal RET pro-
moter (5 bp and1 bp from the transcription start site)
with reduced RET expression by performing functional
assays in human cell lines (Fitze et al. 2003; Garcia-Bar-
celo et al. 2005; Griseri et al. 2005). However, results
were not consistent, so these SNPs cannot unambiguously
be considered as being pathogenic.
In this study, we attempt to further investigate the re-
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gion of interest by sequencing 33 kb—from 10 kb up-
stream of the gene through 23 kb of intron 1 and exon
2—in a patient homozygous for the common risk hap-
lotype and in a healthy control individual homozygous
for the most common nonrisk haplotype. To sequence this
33-kb region (NCBI genomic position: 42846516 bp–
42880012 bp [chromosome 10]), 49 primer sets were
designed. The average size of the amplification product
was 750 bp, and, between amplicons, there was an over-
lap of ∼50 bp. Primer sequences can be found on the
Hirschsprung Disease Web site of the University of Gron-
ingen Department of Genetics. Samples were sequenced
by BaseClear. By restricting the comparison (for economic
reasons) to a single patient and a single control individual,
one runs the risk of missing SNPs in the comparison.
However, since the haplotypes are quite common, one
might expect that a SNP responsible for the difference
will have a very high probability to be found.
Sequence comparison between the two sequences (the
sequence of the common HSCR haplotype and that of
the most common control haplotype) revealed 86 dif-
ferent sequence variants (table 1). In intron 1, a deletion
of 12 bp was found (IVS3991), as were two insertions
(IVS15274insCT and IVS111084insG) and two 2-
base substitutions (IVS1638384GGrCC and IVS1
6567CGrGC). The remaining 81 variations are all SNPs.
All the variations were found in a homozygous state
in the patient’s DNA as well as in the control’s DNA.
Table 1 includes, as indicated, five of the six SNPs that
form our previously identified haplotype. The sixth mar-
ker, IVS1126GrT, is not included, since the patient’s
DNA and the control’s DNA had the same allele at this
locus. Twenty variants were located in the region up-
stream of the gene, 65 are located in intron 1, and 1 is
located in exon 2 (table 1). The sequence-variation fre-
quency in the upstream region is 1/536 bp, and, for the
intronic region, it is 1/353 bp. This might indicate a
tighter selection mechanism on the upstream sequence,
as a consequence of the possible presence of more-im-
portant regulatory regions. On the other hand, the com-
mon risk haplotype observed in our patients also spans
the whole of intron 1, supporting the hypothesis that
this intronic region might also be involved in the regu-
lation of RET expression.
Since our aim was to delimit the HSCR-associated
region by further genotyping, we selected from these 86
sequence variations the most likely candidate disease-
associated variants. Variants were first selected on the
basis of their location in regions that are conserved
among vertebrate species. To identify evolutionarily con-
served domains within this 33-kb region, we compared
the human genomic sequence with the genomic DNA
sequences of chimpanzee (Pan troglodytes), rat (Rattus
norvegicus), mouse (Mus musculus), and chicken (Gallus
gallus) (downloaded from the UCSC Genome Browser
database). Sequence comparisons between these species
were performed using the freely available tool MULAN
(MUltiple sequence Local AligNment and conservation
visualization tool) and the software package Clone Man-
ager Professional Suite (Needleman-Wunsch method).
Figure 1 shows the level of evolutionary conservation
between the chimpanzee, mouse, rat, and chicken, with
the human sequence as a reference. Rat and mouse ge-
nomes show a comparable level of conservation with the
human sequence. There are 11 regions with a similarity
170%. The distal part of the human intron 1 shows no
homology with the mouse and rat counterparts, except
for the short region just downstream of exon 2 and exon
2 itself. Furthermore, it has to be noticed that the ro-
dents’ intron 1 is only 12 kb long—roughly half as long
as the human intron 1. Moreover, in the mouse genome,
homology to the human intron 1 is found in a region
30 kb upstream of the gene and also in intron 18 of the
mouse Ret gene (data not shown). This could mean that
this region has been translocated either in rodents or in
primates, since the chimpanzee’s intron 1 is highly sim-
ilar to that of humans.
A region that is almost identical between rodents and
primates (99.5%) is located between the positions 5.7
kb and 5.2 kb, with reference to RET ATG (fig. 1).
Between the human and chicken sequences, there is hardly
any significant similarity. This might imply that conserved
transcriptional regulation of RET is restricted to mam-
mals. However, similarity was found in the region be-
tween positions 9.3 kb and 9.7 kb (corresponding to
the human sequence), where strong homology with chim-
panzee, rat, and mouse sequences is observed as well
(fig. 1). This is the only region conserved among all of
the species studied. The second region of moderate con-
servation in chicken is located in the distal part of the
sequence at the beginning of exon 2.
The sequence of the chimpanzee is almost identical to
the human sequence, except for a number of repeats, point
mutations, and small deletions/insertions. A puzzling ob-
servation is that exon 1 is missing from the chimpanzee
genome database. Instead, there is a repeated sequence in
this position. This is probably a sequencing error, since
the chimpanzee genome database is still not assembled
well enough, and many gaps exist between contigs.
The occurrence of sequence homology between differ-
ent species in noncoding regions (including promoter and
intron regions) might suggest that these conserved regions
contain binding sites for relevant transcription factors. We
therefore checked the sequenced genomic region for the
presence of specific consensus binding elements for mam-
malian transcription factors, and we determined whether
the identified DNA variants were present in these putative
transcription factor consensus binding elements. For this,
we used the UCSC Genome Browser and the program
GENEQUEST from the DNASTAR software package. We
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Figure 1 MULAN plots displaying the percentages of similarity of the 5′ region of the RET locus in the chicken, rat, mouse, and chimpanzee
genomic sequences, compared with the human sequence as a reference. The horizontal gray line indicates 70% identity. The top panel of the
figure depicts the positions of the 31 SNPs that are located within putative transcription factor binding sites. Those indicated in green fall in
one of the evolutionarily conserved regions. The upper scale refers to RET ATG (0 kb). The lower scale represents the length of the whole
region. TFBSs p transcription factor binding sites.
aimed to find DNA elements that were lost in the patient’s
DNA that might result in diminished expression and
might thereby explain the HSCR phenotype. We detected
31 base changes that led to the loss of such a binding site
(table 2). Among the binding sites that were found, many
were recognized by ubiquitous transcription factors such
as SP1, AP2, or NF. We also found, however, consensus
binding elements for more specifically acting factors, such
as Msx1, that play a role in neural tube development
(table 2). At the top of figure 1, the approximate positions
are given of those SNPs that cause loss of the putative
transcription factor binding sites. Eight of them fall in the
previously mentioned evolutionarily conserved regions
(4201GrA,1260TrC,719CrT, IVS12820TrC,
IVS12846GrT, IVS13104CrT, IVS15094TrA,
and IVS19494CrA) (fig. 1; table 2).
Previously, we reported 23 different haplotypes (Bur-
zynski et al. 2004), of which 4 were homozygously present
in our patients or controls (2 risk haplotypes and 2 non-
risk haplotypes). We typed individuals homozygous for
these four haplotypes by direct sequencing (used for seven
SNPs) and by digestion (HpyCH4IV) of amplified PCR
products (used for one SNP, IVS19494CrA). For four
of the eight markers, including the two most proximal
SNPs,4201GrA and1260TrC, the same alleles were
identified on both the risk and nonrisk haplotypes (fig.
2). Four SNPs (719CrT, IVS12846, IVS13104, and
IVS19494) showed perfect segregation with the disease,
meaning that one allele was present on a risk haplotype
and the other was on a nonrisk haplotype. Therefore,
the candidate region for the causal mutation in HSCR is
likely bordered by SNP1260CrA and SNP IVS1
126GrT. As SNPs, 4201GrA and 1260TrC are
not part of the candidate region; only SNPs 719CrT,
IVS12820TrC, IVS12846GrT, IVS13104CrT,
IVS15094TrA, and IVS19494CrA were subse-
quently genotyped in all of our families with HSCR.
DNA samples used for genotyping were obtained after
the receipt of written informed consent from patients
with sporadic HSCR and from their parents (only those
who resided in the Netherlands); the DNA samples were
subsequently referred to clinical genetics centers. Almost
all of the families in our study (113 of 117) consist of
two parents and an affected child (trios). In three cases,
only one parent was available for the study, and one
patient participated with his child and spouse. Sixty-four
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Table 2
Sequence Variations in the Common Risk Haplotype with Loss of a Hypothetical Consensus
Binding Element
Position and Type
of Variant
NCBI dbSNP
Accession No. Transcription Factor
7359ArC rs2505990 CSS(2)
6347GrA rs2505991 AP2/SP1, SP1erk
4201GrA rs2082107 SP1-YB1, ApoE-B1
3820CrT rs2505994 USF-APP, IgHC.4, NF-mu-E1-CS, GT-2B-RS
3054GrA rs2505995 HC5
2897TrC rs2505996 NF-E1, NF-E1.6
1260TrC rs2505999 MEF3_B
719CrT rs2435366 SP1erk, AP2/SP1, SP1-TPI(4), SP1-hsp70, hsp70.2,
SP1-IE-3.3,4.5
IVS12820TrC rs1864411 Uteroglobin HS-2.4-C, AP2-TBXAS1
IVS12846GrT rs1864410 AP2/SP1, SP1-erk1(1), JCV
IVS13104CrT rs1864408 NFI-CS3, ELP/SF1/FT2F1, SF1-CYP21
IVS15094TrA rs2506016 BPV-E2.CS2, E2-RS1
IVS16294TrC rs2506020 ETS-1
IVS1638384GGrCC … SP1 complement factor, SP1-CS4, HC3
IVS16411GrA … AP2 CS4
IVS16751TrC rs1897001 PEA3, IE1.2
IVS16813CrT rs1896999 Site-I(2)
IVS17445ArC rs2506008 HNF-5
IVS19494CrA rs2506004 E1AF
IVS110813ArG … Msx1
IVS110032CrT rs2435344 E2A-CAMLG, E2A, USFAPP
IVS110017CrT rs2435345 SP1-TPI(4), AP-2-b
IVS17593GrA rs752975 GR-MT-IIA
IVS17298GrA … AP2-CS5
IVS15791CrT rs2505541 AP2-CS5
IVS15127CrG … TFIID-EIIa
IVS15038CrT rs2505539 Uteroglobin HS-2.4-C, T antigen
IVS15005ArG rs2435346 SP1YB1, MyoD-MCK right site, site F (4,5), AP2-APP
IVS13748CrT rs2505537 AP2-b
IVS13702TrA rs2505536 GR-uteroglobin(1,2), GR/Prconnexin43
patients were screened by means of denaturing gradient
gel electrophoresis and sequence analysis (Hofstra et al.
2000) and were found to be negative for RET mutations.
These 64 were selected from an initial group of 72 pa-
tients with sporadic HSCR, of whom 8 appeared to carry
a RET mutation. Fifty-three of the patients included in
the study have not been screened for a RET mutation,
which therefore may be present in a few of them. As
controls for the transmitted haplotypes, the nontrans-
mitted haplotypes of unaffected parents were used, as is
also the case in the haplotype-relative-risk method (Falk
and Rubinstein 1987; Terwilliger and Ott 1992). The
two nontransmitted haplotypes within each trio form
pseudocontrol genotypes. Under the hypothesis of ran-
dom mating in our study population, these pseudocon-
trol genotypes are expected to be similar to genotypes
of population controls and can be used to provide es-
timates of the number of heterozygotes and homo-
zygotes in the population, as well as estimates of the
odds ratios of their risk of developing HSCR. The results
of the transmission/disequilibrium tests (TDTs) and the
association tests for the six newly selected SNPs and
the six SNPs from our previous study are shown in fig-
ure 3. All SNPs were strongly associated. For six of
them (200GrA [SNP-5], IVS12820TrC, IVS1
2846GrT, IVS13104CrT, IVS15094TrA, and
IVS19494CrA), the association was stronger than for
the other six. Corresponding allele frequencies were all
in the range of 66.7%68.6% among patients and
21.8%25.4% among pseudocontrols. Haplotype anal-
ysis showed that these six risk alleles are present on the
same risk haplotype, CTACCTTAAATA (table 3). Its
frequency is estimated to be 53.3% among patients and
15.9% among controls (table 3). Another haplotype,
CCACCTTAAATA, which only differs from the risk
haplotype at the second SNP (which also contains the
risk alleles of our previous six-locus risk haplotype), was
present in 6.01% of patients and in 1.5% of controls.
Since this haplotype also confers an increased risk, it
does not contribute to further restriction of our candi-
date region.
The question remains: which of the identified variants
is contributing to the disease development? Several can-
didates have already been put forward. SNPs200GrA
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Figure 2 Haplotypes consisting of 14 SNPs—6 from our previous risk haplotype and 8 newly selected ones—of four homozygous
individuals. Individuals homozygous for one of the haplotypes identified in our previous study (the corresponding SNPs are indicated in plain
typeface) were typed for eight new SNPs (indicated in bold typeface). They were also homozygous for all eight new SNPs. Risk alleles are in
dark gray boxes; nonrisk alleles are in light gray boxes. freq T p frequency of transmitted haplotype; freq NTp frequency of nontransmitted
haplotype.
Figure 3 Results of allelic and genotypic association tests and
TDT for the 5′ RET locus SNPs. Results presented regard markers
characterized in the previous study (Burzynski et al. 2004) as well as
six new loci. For the single-locus allelic and genotypic association
analyses, the frequencies of the alleles and the genotypes, respectively,
were compared between patients and pseudocontrols by use of a x2
test. Transmission distortion of each allele versus all other alleles to-
gether was tested and combined in a multiallelic TDT (Spielman and
Ewens 1996). All P values and CIs were corrected for multiple testing
for independent tests by use of a Bonferroni correction.
(SNP-5) and 196ArC (SNP-1), which were subjects of
functional studies (Fitze et al. 2003; Garcia-Barcelo et al.
2005; Griseri et al. 2005) and are part of the risk hap-
lotype identified in our previous study (Burzynski et al.
2004), were not present among the eight variants we se-
lected. These two candidate variations did not fulfill our
current criteria, which are based on interspecies sequence
conservation and changes in transcription factor binding
sites. Nevertheless, Fitze et al. (2003) claimed that SNP
200GrA, in particular, caused reduced RET promoter
activity. Griseri et al. (2005) found rather contradictory
results, as they observed strong cell line dependency and
no consistent results in promoter activity assays. These
two SNPs are localized in close proximity to a transcrip-
tion start site. They are part of the RET basal promoter,
which is conserved in human, mouse, and rat. Because of
these contradictory results and because of our findings
presented here, it is likely that they are in linkage dis-
equilibrium with mutation(s) lying nearby. The closest
polymorphism that we found upstream of SNP-5 is SNP
719CrT, one of our eight selected polymorphisms. It
causes the loss of several putative sites recognized by the
SP1 and AP2 transcription factors. It is likely that this
SNP is still a part of the basal promoter and, thus, is a
good candidate for future promoter activity studies. Three
other SNPs (IVS12820TrC, IVS12846GrT, and
IVS13104CrT) lie close together and are located in the
proximal part of intron 1, in a region of strong sequence
conservation between species (fig. 1, peak from 5.7 kb
to 5.2 kb). The most distal SNP of the eight, IVS1
9494CrA, lies in an interesting region, since all species,
including chicken, show homology with the human ge-
nome at this position (fig. 1, peak from9.3 kb to9.7
kb). The occurrence of evolutionarily conserved regions
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located in an intronic sequence supports the idea that
intron 1 is involved in transcriptional regulation. Down-
stream of the last SNP, IVS19494CrA, there is only
one more short region of moderate homology in the
human and rodent sequences (fig. 1, peak from 11.5
kb to 11.6 kb). Intron 1 in the mouse and rat genomes
is only 12 kb long, whereas, in humans, it is 23 kb. This
likely results either from a translocation or deletion of
this sequence in rodent genomes or from an insertion in
primate genomes, since, in the mouse, we found regions
of partial homology to the missing sequence 30 kb up-
stream of Ret and also in intron 18 (data not shown).
On the basis of the statistical analyses, no single SNP
could be identified as being the causal one (fig. 3). Since
the region around SNP IVS19494 is the best-conserved
region—not only in mammals but also in chicken—this
DNA variation is a good candidate for disease suscepti-
bility, although we cannot fully exclude the possibility that
a nearby DNA variation(s) that we might have missed
could actually be responsible for HSCR or could act in
combination with the candidate proposed here. Marker
IVS19494CrA causes the loss of a binding site of the
ETV4 enhancer (ETS variant gene 4 E1A enhancer bind-
ing protein, E1AF [DNA-binding sequence TGGACGT]).
ETV4 is a member of the ETS transcription factor family
and is a downstream nuclear target of RAS-MAP kinase
signaling. Its disturbed functioning was implicated in ma-
lignant tumors, such as ovarian carcinoma and breast
cancer (Davidson et al. 2004). Transcription factors with
an evolutionarily conserved ETS domain play (in general)
important roles in cell development, cell differentiation,
cell proliferation, apoptosis, and tissue remodeling (Oi-
kawa 2004), which suggests that ETV4 can influence the
HSCR phenotype. Functional studies of ETV4 and its
interaction with RET regulatory sequences should fol-
low, to determine the importance of this enhancer in RET
transcription.
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